Alternative initiation regimen of paliperidone palmitate long-acting injectable
Introduction Long-acting injectable antipsychotics (LAIs) hold an important place in the treatment of psychosis. Knowledge of the best way to administer LAIs is important to maximize the efficacy and minimize the side-effects Objectives To assess the effectiveness of flexible doses of palmitate pa...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Cambridge University Press
2022-06-01
|
| Series: | European Psychiatry |
| Subjects: | |
| Online Access: | https://www.cambridge.org/core/product/identifier/S0924933822007283/type/journal_article |
| _version_ | 1827754716194406400 |
|---|---|
| author | I.E. Menendez Gil S.L. Romero Guillena B.O. Plasencia Garcia De Diego |
| author_facet | I.E. Menendez Gil S.L. Romero Guillena B.O. Plasencia Garcia De Diego |
| author_sort | I.E. Menendez Gil |
| collection | DOAJ |
| description |
Introduction
Long-acting injectable antipsychotics (LAIs) hold an important place in the treatment of psychosis. Knowledge of the best way to administer LAIs is important to maximize the efficacy and minimize the side-effects
Objectives
To assess the effectiveness of flexible doses of palmitate paliperidone long-acting injectable (PPLAI) against standard doses in initiation regimen in the subset of acutely hospitalized patients with schizophrenia and other psychosis
Methods
Retrospective, noninterventional study. Group of initiation regimen: A)“Standard-doses” (recommended PPLAI initiation regimen: 150mg-Day-1 and 100mg-Day-8±4days), B)“Low-doses” (any dosage lower than the Standard-dose) C)“High-doses” (150mg-Day-1 and 150mg-Day-8±4days) Effectiveness was measured with the number of psychiatric hospital admission and psychiatric emergency visit 6-months post-discharge. Length of stay of the index hospitalization, adherence to treatment and adverse events was confirmed in the medical record. Concomitant use of biperiden was recorded.
Results
51 patients were included. We found no statistically differences in study variables between groups (Table-1). Table-1.
Standard doses(n=31)
Low-doses(n=13)
High-doses(n=7)
Length of stay mean±sd
17.23±13.09
13.77±9.02
17±10.55
No psychiatric hospitalizations 6-month post-discharge,
%patients( n)
71%(n=22)
84.6%(n=11)
85.7%(n=6)
No psychiatric emergency visits 6-month post-discharge, %patients(n)
61.3%(n=19)
69.2%(n=9)
85.7%(n=6)
Prescription of biperiden 6-month post-discharge, %patients(n)
13.3%(n=4)
0%(n=0)
14.3%(n=1)
Adherence to treatment 6-month post-discharge, %patients(n)
80.6%(n=25)
84.61%(n=11)
57.1%(n=4)
Conclusions
No differences were found in the effectiveness of flexible-doses in PPLAI initiation regimen. The use of low doses of PPLAI could keep the efficacy of the standard dose with a better side effect profile and treatment adherence. The strength of the conclusion is limited by the design and the number of patients.
Disclosure
No significant relationships.
|
| first_indexed | 2024-03-11T07:54:20Z |
| format | Article |
| id | doaj.art-3563374e7d0f44a5b21b054514f2db1b |
| institution | Directory Open Access Journal |
| issn | 0924-9338 1778-3585 |
| language | English |
| last_indexed | 2024-03-11T07:54:20Z |
| publishDate | 2022-06-01 |
| publisher | Cambridge University Press |
| record_format | Article |
| series | European Psychiatry |
| spelling | doaj.art-3563374e7d0f44a5b21b054514f2db1b2023-11-17T05:06:03ZengCambridge University PressEuropean Psychiatry0924-93381778-35852022-06-0165S284S28510.1192/j.eurpsy.2022.728Alternative initiation regimen of paliperidone palmitate long-acting injectableI.E. Menendez Gil0S.L. Romero Guillena1B.O. Plasencia Garcia De Diego2Virgen del Rocio Hospital, Psychiatry, Seville, SpainUGC Salud Mental Virgen Macarena,, Psychiatry, seville, SpainVirgen del Rocio Hospital, Psychiatry, Seville, Spain Introduction Long-acting injectable antipsychotics (LAIs) hold an important place in the treatment of psychosis. Knowledge of the best way to administer LAIs is important to maximize the efficacy and minimize the side-effects Objectives To assess the effectiveness of flexible doses of palmitate paliperidone long-acting injectable (PPLAI) against standard doses in initiation regimen in the subset of acutely hospitalized patients with schizophrenia and other psychosis Methods Retrospective, noninterventional study. Group of initiation regimen: A)“Standard-doses” (recommended PPLAI initiation regimen: 150mg-Day-1 and 100mg-Day-8±4days), B)“Low-doses” (any dosage lower than the Standard-dose) C)“High-doses” (150mg-Day-1 and 150mg-Day-8±4days) Effectiveness was measured with the number of psychiatric hospital admission and psychiatric emergency visit 6-months post-discharge. Length of stay of the index hospitalization, adherence to treatment and adverse events was confirmed in the medical record. Concomitant use of biperiden was recorded. Results 51 patients were included. We found no statistically differences in study variables between groups (Table-1). Table-1. Standard doses(n=31) Low-doses(n=13) High-doses(n=7) Length of stay mean±sd 17.23±13.09 13.77±9.02 17±10.55 No psychiatric hospitalizations 6-month post-discharge, %patients( n) 71%(n=22) 84.6%(n=11) 85.7%(n=6) No psychiatric emergency visits 6-month post-discharge, %patients(n) 61.3%(n=19) 69.2%(n=9) 85.7%(n=6) Prescription of biperiden 6-month post-discharge, %patients(n) 13.3%(n=4) 0%(n=0) 14.3%(n=1) Adherence to treatment 6-month post-discharge, %patients(n) 80.6%(n=25) 84.61%(n=11) 57.1%(n=4) Conclusions No differences were found in the effectiveness of flexible-doses in PPLAI initiation regimen. The use of low doses of PPLAI could keep the efficacy of the standard dose with a better side effect profile and treatment adherence. The strength of the conclusion is limited by the design and the number of patients. Disclosure No significant relationships. https://www.cambridge.org/core/product/identifier/S0924933822007283/type/journal_articleschizophréniapaliperidone palmitate long-actingantipsychoticPsychosis |
| spellingShingle | I.E. Menendez Gil S.L. Romero Guillena B.O. Plasencia Garcia De Diego Alternative initiation regimen of paliperidone palmitate long-acting injectable European Psychiatry schizophrénia paliperidone palmitate long-acting antipsychotic Psychosis |
| title | Alternative initiation regimen of paliperidone palmitate long-acting injectable |
| title_full | Alternative initiation regimen of paliperidone palmitate long-acting injectable |
| title_fullStr | Alternative initiation regimen of paliperidone palmitate long-acting injectable |
| title_full_unstemmed | Alternative initiation regimen of paliperidone palmitate long-acting injectable |
| title_short | Alternative initiation regimen of paliperidone palmitate long-acting injectable |
| title_sort | alternative initiation regimen of paliperidone palmitate long acting injectable |
| topic | schizophrénia paliperidone palmitate long-acting antipsychotic Psychosis |
| url | https://www.cambridge.org/core/product/identifier/S0924933822007283/type/journal_article |
| work_keys_str_mv | AT iemenendezgil alternativeinitiationregimenofpaliperidonepalmitatelongactinginjectable AT slromeroguillena alternativeinitiationregimenofpaliperidonepalmitatelongactinginjectable AT boplasenciagarciadediego alternativeinitiationregimenofpaliperidonepalmitatelongactinginjectable |